Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) CMO Noah Rosenberg acquired 4,200 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was bought at an average cost of $4.91 per share, with a total value of $20,622.00. Following the purchase, the chief marketing officer owned 6,557 shares in the company, valued at $32,194.87. The trade was a 178.19% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Verrica Pharmaceuticals Stock Performance
NASDAQ VRCA opened at $4.99 on Thursday. The firm’s fifty day moving average price is $5.64 and its two-hundred day moving average price is $5.90. The stock has a market cap of $85.73 million, a PE ratio of -2.99 and a beta of 1.49. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $9.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Wall Street Zen lowered Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. HC Wainwright initiated coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.50.
Hedge Funds Weigh In On Verrica Pharmaceuticals
Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in Verrica Pharmaceuticals by 22.6% in the first quarter. Renaissance Technologies LLC now owns 32,360 shares of the company’s stock valued at $171,000 after acquiring an additional 5,960 shares during the last quarter. XTX Topco Ltd acquired a new stake in Verrica Pharmaceuticals during the 4th quarter valued at approximately $122,000. Quadrature Capital Ltd bought a new position in Verrica Pharmaceuticals during the 4th quarter worth approximately $99,000. Man Group plc bought a new position in Verrica Pharmaceuticals during the 4th quarter worth approximately $94,000. Finally, Armistice Capital LLC lifted its position in shares of Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after purchasing an additional 479,732 shares during the period. 42.45% of the stock is currently owned by institutional investors.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.
Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.
Featured Articles
- Five stocks we like better than Verrica Pharmaceuticals
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
